Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Smoldering Multiple Myeloma × daratumumab × Clear all

Phase

Status

Sponsor Class

OTHER 2 INDUSTRY 2 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 14 Smoldering Multiple Myeloma 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Plasmablastic Lymphoma 1 Disease 1

Interventions

dexamethasone acetate 1 dexamethasone 21-phosphate 1 daratumumab 1 auricularum 1 Lenalidomide 1 Dexamethasone 1 Calcium Dobesilate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03937635 2026-03-02

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡